Jump to content

User:Mr. Ibrahem/Avatrombopag

From Wikipedia, the free encyclopedia

Mr. Ibrahem/Avatrombopag
Clinical data
Pronunciationa" va trom' boe pag
Trade namesDoptelet
Other namesAvatrombopag maleate
AHFS/Drugs.comMonograph
MedlinePlusa618032
License data
Routes of
administration		By mouth
Drug classThrombopoietin receptor agonist[1]
Legal status
Legal status
  • US: ℞-only
  • EU: Rx-only
  • In general: ℞ (Prescription only)
Identifiers
  • 1-[3-Chloro-5-[[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)-1,3-thiazol-2-yl]carbamoyl]pyridin-2-yl]piperidine-4-carboxylic acid
Chemical and physical data
FormulaC29H34Cl2N6O3S2
Molar mass649.65 g·mol−1
3D model (JSmol)
  • C1CCC(CC1)N2CCN(CC2)C3=C(N=C(S3)NC(=O)C4=CC(=C(N=C4)N5CCC(CC5)C(=O)O)Cl)C6=CC(=CS6)Cl
  • InChI=1S/C29H34Cl2N6O3S2/c30-20-15-23(41-17-20)24-27(37-12-10-35(11-13-37)21-4-2-1-3-5-21)42-29(33-24)34-26(38)19-14-22(31)25(32-16-19)36-8-6-18(7-9-36)28(39)40/h14-18,21H,1-13H2,(H,39,40)(H,33,34,38) checkY
  • Key:OFZJKCQENFPZBH-UHFFFAOYSA-N
 ☒NcheckY (what is this?)

Avatrombopag, sold under the brand name Doptelet, is a medication used to treat low platelets in chronic liver disease when an invasive medical procedure is required.[2][3] It is taken by mouth.[1]

Common side effects include fever, abdominal pain, nausea, headache, tiredness, and peripheral swelling.[2] Other side effects may include blood clots.[2] Use in pregnancy may harm the baby.[2] Safety in pregnancy or breastfeeding is unclear.[1] It is a thrombopoietin receptor agonist, which increases platelet production.[1]

Avatrombopag was approved for medical use in the United States in 2018 and Europe in 2019.[2][3] In the United Kingdom a course of treatment costs the NHS £640 to £960 as of 2020.[4] In the United States this amount is 3,650 USD to 5,500 USD.[5]

References[edit]

  1. ^ a b c d BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1079. ISBN 978-0857114105.
  2. ^ a b c d e f g "Avatrombopag Monograph for Professionals". Drugs.com. Archived from the original on 25 January 2021. Retrieved 16 January 2022.
  3. ^ a b c d "Doptelet EPAR". European Medicines Agency (EMA). 24 April 2019. Archived from the original on 22 May 2020. Retrieved 2 May 2020.
  4. ^ "Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure". Archived from the original on 17 January 2022. Retrieved 16 January 2022.
  5. ^ "Doptelet Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 16 April 2021. Retrieved 16 January 2022.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Avatrombopag&oldid=1099697855"